|
|
Post by cretin11 on Jun 4, 2021 9:55:56 GMT -5
Agreed. To post a negative perspective without any substance to explain the thought or logic has to be considered FUD. It's like any argument when the losing side has nothing better to say other than to resort to name calling. The opportunity certainly exists to follow up and explain why there are "some doubts on the Peds trial. IMO, nothing published or posted to date should lead anyone to think this. Sorry, veritasfiliatemporis, the board has spoken. |
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 9:56:31 GMT -5
You judge positive and negative, and apply your thoughts to share price, Afrezza story is quite different, we all know positive data, we should be aware of the " issues" too, Afrezza did not strike the market, MNKD has been saved by Techno sphere and Dreamboat,David...
|
|
|
|
Post by dh4mizzou on Jun 4, 2021 10:00:11 GMT -5
You judge positive and negative, and apply your thoughts to share price, Afrezza story is quite different, we all know positive data, we should be aware of the " issues" too, Afrezza did not strike the market, MNKD has been saved by Techno sphere and Dreamboat,David... You mention "issues" without providing any data/information to back up your assertion. This is what I'm taking issue with. With the good side we see various outlets, etc. providing the substance. You..... not yet. |
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 10:18:33 GMT -5
Are you the same person? Spreading lies, after 5 years Mannkind is still loosing money and breakeven will arrive from Tyvaso Am I right or wrong? 6 years investing on this company I do not need patents from you.. David
|
|
|
|
Post by radgray68 on Jun 4, 2021 11:33:02 GMT -5
Look at the STAT and Levin study results. 70% fewer severe hypos? Fuggettabouttit. We're finally ready to rock this trial like Al Mann always wanted. Finally, we can show superiority. I repeat, SUPERIORITY! Thanks to management's efforts of the last few years, participants can now be titrated much more aggressively, the biggest failing of the trials from before approval. The duration of this trial alone will give more time for A1c levels to show even more significant improvement than stat and Levin.
There is evidence out there to back my enthusiasm. Unfortunately, it can't quell everybody's fear, uncertainty and doubt. Good luck to everyone.
|
|
|
|
Post by cretin11 on Jun 4, 2021 11:54:41 GMT -5
Look at the STAT and Levin study results. 70% fewer severe hypos? Fuggettabouttit. We're finally ready to rock this trial like Al Mann always wanted. Finally, we can show superiority. I repeat, SUPERIORITY! Thanks to management's efforts of the last few years, participants can now be titrated much more aggressively, the biggest failing of the trials from before approval. The duration of this trial alone will give more time for A1c levels to show even more significant improvement than stat and Levin. There is evidence out there to back my enthusiasm. Unfortunately, it can't quell everybody's fear, uncertainty and doubt. Good luck to everyone. veritas what is your response to this? Superiority is finally proven. Surely the rapid increase in script count will shortly follow. radgray, mizzou, or anyone else, what is your prediction for weekly script count by end of this year? |
|
|
|
Post by dh4mizzou on Jun 4, 2021 12:20:41 GMT -5
Cretin. I am not Karnak so I don't do prognostication.
|
|
|
|
Post by veritasfiliatemporis on Jun 4, 2021 12:25:07 GMT -5
Superiority has been proven 4 years ago, we all know, I DO NOT EXPECT a miracle, I invest on facts, this board should not be a pumping dumping idiot game, I'll buy under 3.3 If...
|
|
|
|
Post by casualinvestor on Jun 4, 2021 13:03:52 GMT -5
IF the peds trial can prove superiority (a big unknown, despite what we've seen Afrezza do in cases where the people taking it know what they are doing, because in a trial the people taking may not know what they are doing), then that will be huge. It will also provide an immediate reason why prescribers would use it over other options, and therefore they might be more willing to jump through pre-approval hoops.
If the peds trial can prove non-inferiority, and get approved for children, then that will accelerate adoption of Afrezza, but it will be a much slower road.
I expect that corporate profitability will be achieved by the addition of Tyvaso-DPI before the Afrezza product is profitable by itself. The sharing of costs for production will help a lot
|
|
